## JAZZ: Jazz Pharmaceuticals plc - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.1% below STRENGTH zone (3.0-6.0%); PEG 3.90 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-1.8% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($159.65)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. 211,185 Shares in Jazz Pharmaceuticals PLC $JAZZ Acquired by Wedge Capital Management L L P NC**
- Source: MarketBeat | 20251221T121011 | Neutral | Relevance: 100%
- Wedge Capital Management L L P NC recently acquired a new stake of 211,185 shares in Jazz Pharmaceuticals PLC ($JAZZ), valued at approximately $27.83 million. Despite this institutional accumulation, company insiders have been net sellers, divesting over $22 million worth of shares in the last 90 days. Wall Street analysts maintain a "Moderate Buy" rating for JAZZ, with an average price target of $200.47.

**2. Perpetual Ltd Reduces Stock Position in Jazz Pharmaceuticals PLC $JAZZ**
- Source: MarketBeat | 20251220T131021 | Neutral | Relevance: 100%
- Perpetual Ltd significantly reduced its stake in Jazz Pharmaceuticals PLC, selling 32.1% of its shares in Q3 2025. Insider selling has also accelerated, with company executives selling shares worth millions in the last 90 days, though institutional investors still own a large portion of the company. Despite the reduction by Perpetual Ltd and insider selling, analyst sentiment remains largely positive, with a "Moderate Buy" consensus rating and an average price target of $200.47 for JAZZ.

**3. Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Given Average Rating of "Moderate Buy" by Analysts**
- Source: MarketBeat | 20251220T071021 | Somewhat-Bullish | Relevance: 100%
- Jazz Pharmaceuticals (NASDAQ:JAZZ) has received an average "Moderate Buy" rating from 17 brokerages, with an average 12-month price target of $200.47. Recent insider selling saw executives combine to sell over 12,000 shares, and company insiders have collectively sold 129,291 shares valued at approximately $22.7 million in the last quarter, though insiders still own 4.30% of the stock. Shares opened at $166, with a market capitalization of $10.09 billion.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Piper Sandler | $219 | $147 | +49% |
| 2025-11-24 | UBS | $188 | $163 | +15% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Piper Sandler | reit | Overweight |
| 2025-11-24 | UBS | down | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 13 ($5.28M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 49.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 6 |

**Top Holders:**
- Vanguard Group Inc: 9.7% (-3.0%)
- Blackrock Inc.: 9.2% (-4.2%)
- JPMORGAN CHASE & CO: 6.2% (+117.0%)
- Dimensional Fund Adv: 4.7% (+11.8%)
- Capital World Invest: 4.2% (+0.4%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-1.8% 5d) with bearish MACD, trend may be turning.
2. Insider selling cluster: $5.3M in recent transactions.
3. Valuation stretched: PEG 3.9x requires aggressive growth execution.
4. Elevated short interest (9.5%): bears positioning against stock.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 3.90 signals overvaluation risk, limited margin of safety. Forward P/E 7.5x attractive for 179% earnings growth. Analyst sentiment positive (2 raises, avg +32%). Insider selling cluster ($5.3M in 90 days), potential headwind. Institutional flow bullish (3 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $10.3B |
| Beta | 0.31 |
| 52W Range | $95.49 - $182.99 |
| Short Interest | 9.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.90 |
| Forward P/E | 7.5 |
| Current P/E | 20.9 |
| YoY Growth | 179.2% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from 2.9% to 1.1% (-1.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 1.9pp (needs >3.0% for momentum thesis). MRS_5 (-0.1%) diverging from MRS_10 - short-term weakness emerging. Long-term uptrend intact (above SMA200 at 1.34x) but short-term weakness (below SMA20). MACD histogram bearish (-1.23), momentum weakening. RSI neutral at 59. OFD pattern: +MUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.07% (CS: 71) | Neutral |
| RSI_14 | 58.6 | Neutral |
| MACD Histogram | -1.23 | Bearish |
| vs SMA20 | 1.000x | Below |
| vs SMA50 | 1.103x | Above |
| vs SMA200 | 1.338x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $169.67
- **Stop Loss:** $159.65 (5.9% risk)
- **Target:** $179.69 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 119
- **Position Value:** $20,190.73
- **Portfolio %:** 20.19%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-02-24 (Est: $6.43)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.85 | $8.13 | +39.0% |
| 2025Q2 | $-6.25 | $-8.25 | -32.1% |
| 2025Q1 | $4.66 | $1.68 | -63.9% |
| 2024Q4 | $5.81 | $6.60 | +13.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*